Passage BIO, Inc. (PASG): Entry into a Material Definitive Agreement

Passage BIO, Inc. (PASG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Amended and Restated Merger Agreement As previously disclosed, on June 24, 2026, Passage Bio, Inc. (“ Passage Bio ” or the “ Company ”), Peregrine Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the

Event · M&A · definitive agreement
Role
acquirer
Counterparty
Remix Therapeutics, Inc.
Consideration
stock
Expected close
December 24, 2026
Also in this documentOffering · $70M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Sep 3, 2026, 1:37 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 10:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PASG
Neutral
medium confidence
Mentioned
$PASG
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PASGNeutralMed
01

Why it matters

The amendment secures needed capital and clarifies the merger timeline, but introduces new warrant dilution risk.

02

Market read

Primary disclosure of a material merger amendment for a micro‑cap biotech, relevant for investors tracking deal pipelines.

03

What to watch

Potential tax benefits of the two‑step structure and the timing of the $70 M financing could improve balance‑sheet strength.

Relevance 6/10Novelty 7/10Timing: filed Sep 2 2026

Background

Passage BIO previously announced a merger with Remix Therapeutics; this filing updates the agreement and financing terms.

Company-level read

Ticker impact

$PASGNeutralMedium confidence
Context

Passage BIO filed an 8‑K announcing an amended and restated merger agreement and a $70 M concurrent financing.

Expected impact

Short‑term volatility expected; price may dip on dilution concerns, then stabilize as deal progresses.

Evidence & confidence

Deal terms unchanged materially, but new financing and warrant structure introduce execution risk.

Market effects

Biotech M&A activity may increase as smaller firms seek capital via merger structures.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact beyond niche biotech merger market.

Counterpoint

The added pre‑funded warrants could heavily dilute existing shareholders, making the deal less attractive.

Key entities

  • Passage BIO, Inc.

    Biotech firm executing the merger.

  • Remix Therapeutics, Inc.

    Target company in the merger.

Related articles

$PASGMed

Passage Bio Received Notice of Noncompliance

Passage Bio received a noncompliance notice from Nasdaq for failing to meet the $2.5M stockholders' equity requirement, reporting only $50,000. The company expects its pending merger with Remix Therapeutics to resolve the issue, with shares expected to trade under the symbol RMTX post-merger.

$ASTSMed

AST SpaceMobile Sinks 8% as New Offering Filing Revives Dilution Fears

AST SpaceMobile (ASTS) fell 8% after filing for a new securities sale, raising dilution concerns. The company's share count rose from 200M to 300M between late 2024 and Q3 2026. AT&T (T) and Vodafone (VOD), which have stakes in AST, are also affected. AST's free cash flow was negative $1.8B over the last four quarters, with analysts expecting negative free cash flow through 2028.